
Humana (HUM) Stock Forecast & Price Target
Humana (HUM) Analyst Ratings
Bulls say
Humana is in a favorable position in the healthcare industry, with a focus on government-sponsored programs and a growing membership base. The company's multi-year earnings recovery plan, including a target of at least 3% Medicare Advantage margin by 2028, is on track with key metrics such as utilization and risk scores tracking in line or better than guidance and indications of progress in 2027. Humana's proactive moves to optimize its balance sheet and divest non-core assets further supports its financial health.
Bears say
Humana is heavily reliant on government-sponsored healthcare programs, leaving them vulnerable to potential policy and regulatory changes. The company is also facing pressure from increasing competition in the Medicare Advantage market. Additionally, concerns about the impact of flu and weather on utilization trends, as well as ongoing cost initiatives, may limit potential earnings growth.
This aggregate rating is based on analysts' research of Humana and is not a guaranteed prediction by Public.com or investment advice.
Humana (HUM) Analyst Forecast & Price Prediction
Start investing in Humana (HUM)
Order type
Buy in
Order amount
Est. shares
0 shares